• 四川大學(xué)華西醫(yī)院核醫(yī)學(xué)科（四川成都 610041）;

引用本文： 黃蕤,李林. 分化型甲狀腺癌的放射性碘-131治療. 中國普外基礎(chǔ)與臨床雜志, 2012, 19(8): 814-817. doi: 復(fù)制

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma[J]. N Engl J Med， 1998， 338(5)：297-306.
2. Siegel R， Ward E， Brawley O， et al. Cancer statistics， 2011：the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J]. CA Cancer J Clin， 2011， 61(4)：212-236.
3. Wang Y， Wang W. Increasing incidence of thyroid cancer in Shanghai， China， 1983-2007[J]. Asia Pac J Public Health， 2012， Mar 16. [Epub ahead of print].
4. 錢碧云， 何敏， 陳可欣， 等. 天津城市居民甲狀腺乳頭狀癌發(fā)病率和構(gòu)成比的長期時間趨勢分析[J]. 中國實(shí)用外科雜志， 2011， 31(5)：420-422.
5. Becker DV， Clark TS. Radioiodine and thyroid disease：the beginning[J]. Semin Nucl Med， 1996， 26(3)：155-164.
6. Cooper DS， Doherty GM， Haugen BR， et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid， 2009， 19(11)：1167-1214.
7. Taylor T， Specker B， Robbins J， et al. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma[J]. Ann intern Med， 1998， 129(8)：62-627.
8. Tsang RW， Brierley JD， Simpson WJ， et al. The effects of surgery， radioiodine， and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma[J]. Cancer， 1998， 82(2)：375-388.
9. Mazzaferri EL， Kloos RT. Clinical review 128：Current approaches to primary therapy for papillary and follicular thyroid cancer[J]. J Clin Endocrinol Metab， 2001， 86(4)：1447-1463.
10. Wartofsky L， Sherman Si， Gopal J， et al. The use of radioactive iodine in patients with papillary and follicular thyroid cancer[J]. J Clin Endocrinol Metab， 1998， 83(12)：4195-4203.
11. Jonklaas J， Sarlis NJ， Litofsky D， et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy[J]. Thyroid， 2006， 16(12)：1229-1242.
12. 匡安仁. 131I治療分化型甲狀腺癌[A]//臨床技術(shù)操作規(guī)范-核醫(yī)學(xué)分冊[M]. 北京：人民軍醫(yī)出版社， 2004：178-180.
13. Padovani R， Kasamatsu TS， Nakabashi CC， et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy[J]. Thyroid， 2012， Jun 6. [Epub ahead of print].
14. Hocevar M， Auersperg M， Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery[J]. Eur J Surg Oncol， 1997， 23(3)：208-210.
15. 何英， 潘明志， 戚忠智. 131I-SPECT/CT融合顯像診斷分化型甲狀腺癌轉(zhuǎn)移灶的臨床價值[J]. 四川大學(xué)學(xué)報（醫(yī)學(xué)版）， 2010， 41(4)：734-736.
  1. 1. Schlumberger MJ. Papillary and follicular thyroid carcinoma[J]. N Engl J Med， 1998， 338(5)：297-306.
  2. 2. Siegel R， Ward E， Brawley O， et al. Cancer statistics， 2011：the impact of eliminating socioeconomic and racial disparities on premature cancer deaths[J]. CA Cancer J Clin， 2011， 61(4)：212-236.
  3. 3. Wang Y， Wang W. Increasing incidence of thyroid cancer in Shanghai， China， 1983-2007[J]. Asia Pac J Public Health， 2012， Mar 16. [Epub ahead of print].
  4. 4. 錢碧云， 何敏， 陳可欣， 等. 天津城市居民甲狀腺乳頭狀癌發(fā)病率和構(gòu)成比的長期時間趨勢分析[J]. 中國實(shí)用外科雜志， 2011， 31(5)：420-422.
  5. 5. Becker DV， Clark TS. Radioiodine and thyroid disease：the beginning[J]. Semin Nucl Med， 1996， 26(3)：155-164.
  6. 6. Cooper DS， Doherty GM， Haugen BR， et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer[J]. Thyroid， 2009， 19(11)：1167-1214.
  7. 7. Taylor T， Specker B， Robbins J， et al. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma[J]. Ann intern Med， 1998， 129(8)：62-627.
  8. 8. Tsang RW， Brierley JD， Simpson WJ， et al. The effects of surgery， radioiodine， and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma[J]. Cancer， 1998， 82(2)：375-388.
  9. 9. Mazzaferri EL， Kloos RT. Clinical review 128：Current approaches to primary therapy for papillary and follicular thyroid cancer[J]. J Clin Endocrinol Metab， 2001， 86(4)：1447-1463.
  10. 10. Wartofsky L， Sherman Si， Gopal J， et al. The use of radioactive iodine in patients with papillary and follicular thyroid cancer[J]. J Clin Endocrinol Metab， 1998， 83(12)：4195-4203.
  11. 11. Jonklaas J， Sarlis NJ， Litofsky D， et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy[J]. Thyroid， 2006， 16(12)：1229-1242.
  12. 12. 匡安仁. 131I治療分化型甲狀腺癌[A]//臨床技術(shù)操作規(guī)范-核醫(yī)學(xué)分冊[M]. 北京：人民軍醫(yī)出版社， 2004：178-180.
  13. 13. Padovani R， Kasamatsu TS， Nakabashi CC， et al. One month is sufficient for urinary iodine to return to its baseline value after the use of water soluble iodinated contrast agents in post-thyroidectomy patients requiring radioiodine therapy[J]. Thyroid， 2012， Jun 6. [Epub ahead of print].
  14. 14. Hocevar M， Auersperg M， Stanovnik L. The dynamics of serum thyroglobulin elimination from the body after thyroid surgery[J]. Eur J Surg Oncol， 1997， 23(3)：208-210.
  15. 15. 何英， 潘明志， 戚忠智. 131I-SPECT/CT融合顯像診斷分化型甲狀腺癌轉(zhuǎn)移灶的臨床價值[J]. 四川大學(xué)學(xué)報（醫(yī)學(xué)版）， 2010， 41(4)：734-736.